Zynex Appoints Vice President of Reimbursement and Billing

LONE TREE, Colo.–(BUSINESS WIRE)–Zynex, Inc. (OTCBB: ZYXI),
a provider and developer of non-invasive medical devices for
electrotherapy and stroke rehabilitation, neurological diagnosis and
cardiac monitoring, announced the hiring of Keith White as Vice
President of Reimbursement and Billing. Mr. White will start on
September 19, 2011 and will report directly to Thomas Sandgaard, Chief
Executive Officer.

“We believe Mr. White brings a tremendous
amount of industry experience that will strengthen our management team
and help us continue to improve and execute our successful reimbursement
strategy.”

Mr. White has over 20 years of healthcare and senior management
experience, specifically in the electrotherapy market space, and
possesses an in-depth knowledge of the complex healthcare coding and
reimbursement guidelines. Mr. White most recently served as President
for Aquarius Water Conditioning, Inc., and spent 20 years in various
management positions with Empi, Inc., a DJO Global Inc. company,
including Director of Sales Operations and Patient Care Services and
Billing. Empi, Inc. is a major electrotherapy company in the industry.

Thomas Sandgaard, CEO stated, “We believe Mr. White brings a tremendous
amount of industry experience that will strengthen our management team
and help us continue to improve and execute our successful reimbursement
strategy.” Mr. Sandgaard continued, “Because of Mr. White’s extensive
electrotherapy industry billing and reimbursement background, we believe
he will be a good fit for our rapidly growing Zynex Medical subsidiary.”

Mr. White holds a B.A. degree in Business Management, from Bethel
College.

About Zynex

Zynex, Inc. (founded in 1996), operates under three primary business
segments; Zynex Medical, Zynex NeuroDiagnostics and Zynex Monitoring
Solutions. Zynex Medical engineers, manufactures, markets and sells its
own design of electrotherapy medical devices for standard digital
electrotherapy, used for pain relief, pain management and stroke and
spinal cord injury rehabilitation. Zynex Medical’s product lines are
fully developed, FDA-cleared, commercially sold, and have been developed
to uphold the Company’s mission
of improving the quality of life for patients suffering from impaired
mobility due to stroke, spinal cord injury, or debilitating and chronic
pain. Zynex NeuroDiagnostics, currently in the development stage, has
been established to market EMG, EEG, sleep pattern, auditory and nerve
conductivity neurological diagnosis devices through product development
or acquisitions. Zynex Monitoring Solutions, currently in the
development stage, has been established to develop and market medical
devices for non-invasive cardiac monitoring.

For additional information, please visit: http://www.ir-site.com/zynex/default.asp.

Safe Harbor Statement

Certain statements in this release are “forward-looking” and as such are
subject to numerous risks and uncertainties. Actual results may vary
significantly from the results expressed or implied in such statements.
Factors that could cause actual results to materially differ from
forward-looking statements include, but are not limited to, the need to
obtain additional capital in order to grow our business, our ability to
engage additional sales representatives, the success of such additional
sales representatives, the need to obtain FDA clearance and CE marking
of new products, the acceptance of new products as well as existing
products by doctors and hospitals, larger competitors with greater
financial resources, the need to keep pace with technological changes,
our dependence on the reimbursement from insurance companies for
products sold or rented to our customers, acceptance of our products by
health insurance providers, our dependence on third party manufacturers
to produce our goods on time and to our specifications, implementation
of our sales strategy including a strong direct sales force, the
uncertain outcome of pending material litigation and other risks
described in our filings with the Securities and Exchange Commission
including the “Risk Factors” section of our Annual Report on Form 10-K
for the year ended December 31, 2010.